SINOHYTEC (02402) is expected to incur a net loss attributable to shareholders of approximately 550 million to 720 million yuan in 2025, an increase of 20.50% to 57.74% year-on-year.
Yihuatong (02402) announced that, according to preliminary calculations by the finance department, it is expected to achieve a net loss attributable to the owners of the parent company of approximately RMB 550 million to RMB 720 million in the year 2025, representing an increase in year-on-year losses of 20.50% to 57.74%. It is also expected to achieve a net loss attributable to the owners of the parent company excluding non-recurring gains and losses of approximately RMB 600 million to RMB 780 million in 2025, representing an increase in year-on-year losses of 10.55% to 43.71% compared to the previous year.
SINOHYTEC (02402) announced that, according to the preliminary calculations by the finance department, it is expected to incur a net loss attributable to owners of the parent company of approximately RMB 550 million to RMB 720 million in the fiscal year 2025, representing an increase of 20.50% to 57.74% compared to the corresponding period of the previous year. It is also expected to incur a net loss attributable to owners of the parent company, excluding non-recurring gains and losses, of approximately RMB 600 million to RMB 780 million in 2025, representing an increase of 10.55% to 43.71% compared to the corresponding period of the previous year.
Based on prudent accounting principles, the company's credit impairment losses and asset impairment losses increased year-on-year during the reporting period, exacerbating the company's operating losses.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


